Zoetis Inc (NYSE:ZTS) Shares Purchased by Charter Trust Co.

Charter Trust Co. grew its stake in shares of Zoetis Inc (NYSE:ZTS) by 16.0% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 7,526 shares of the company’s stock after acquiring an additional 1,039 shares during the period. Charter Trust Co.’s holdings in Zoetis were worth $758,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of ZTS. BlackRock Inc. grew its holdings in Zoetis by 2.2% in the first quarter. BlackRock Inc. now owns 37,486,408 shares of the company’s stock worth $3,773,759,000 after purchasing an additional 795,558 shares during the last quarter. Vanguard Group Inc grew its holdings in Zoetis by 0.8% in the third quarter. Vanguard Group Inc now owns 35,947,496 shares of the company’s stock worth $3,291,353,000 after purchasing an additional 293,614 shares during the last quarter. Oregon Public Employees Retirement Fund grew its holdings in Zoetis by 9,042.7% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 14,335,563 shares of the company’s stock worth $168,000 after purchasing an additional 14,178,765 shares during the last quarter. Polen Capital Management LLC lifted its stake in shares of Zoetis by 1.9% during the fourth quarter. Polen Capital Management LLC now owns 9,553,567 shares of the company’s stock worth $817,212,000 after buying an additional 178,893 shares during the period. Finally, FMR LLC lifted its stake in shares of Zoetis by 209.7% during the fourth quarter. FMR LLC now owns 7,245,748 shares of the company’s stock worth $619,801,000 after buying an additional 4,905,887 shares during the period. 90.20% of the stock is owned by hedge funds and other institutional investors.

Several research firms have recently commented on ZTS. Craig Hallum lifted their price objective on shares of Zoetis from $114.00 to $132.00 and gave the stock a “buy” rating in a research note on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating and set a $130.00 price objective (up from $116.00) on shares of Zoetis in a research note on Wednesday, June 12th. Barclays began coverage on shares of Zoetis in a research note on Tuesday, June 11th. They set an “overweight” rating and a $120.00 price objective for the company. Guggenheim assumed coverage on shares of Zoetis in a research note on Thursday, May 23rd. They set a “buy” rating and a $114.00 price objective for the company. Finally, BMO Capital Markets boosted their target price on shares of Zoetis from $101.00 to $105.00 and gave the company a “market perform” rating in a research report on Thursday, May 9th. Six research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Zoetis presently has an average rating of “Buy” and a consensus target price of $108.25.

In other Zoetis news, CFO Glenn David sold 8,191 shares of the stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $102.22, for a total transaction of $837,284.02. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Roxanne Lagano sold 2,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $101.89, for a total transaction of $203,780.00. Following the sale, the insider now owns 30,727 shares in the company, valued at $3,130,774.03. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 78,614 shares of company stock worth $8,096,895. Company insiders own 0.29% of the company’s stock.

Shares of ZTS stock traded up $5,913,999,787.24 on Friday, reaching $5,913,999,900.00. 2,098,448 shares of the company were exchanged, compared to its average volume of 2,232,859. The company has a market cap of $54.13 billion, a P/E ratio of 1,889,456,837.06, a price-to-earnings-growth ratio of 2.82 and a beta of 0.87. The firm has a 50-day moving average of $106.85. The company has a debt-to-equity ratio of 2.84, a quick ratio of 2.79 and a current ratio of 4.05. Zoetis Inc has a 1 year low of $78.90 and a 1 year high of $116.47.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $0.88 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.09. Zoetis had a net margin of 23.47% and a return on equity of 73.66%. The business had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.45 billion. During the same quarter in the prior year, the company posted $0.75 EPS. The business’s revenue for the quarter was up 6.5% on a year-over-year basis. Analysts anticipate that Zoetis Inc will post 3.48 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 19th will be issued a $0.164 dividend. The ex-dividend date is Thursday, July 18th. This represents a $0.66 annualized dividend and a dividend yield of 0.00%. Zoetis’s dividend payout ratio is currently 21.09%.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Read More: Google Finance Portfolio Tips and Tricks

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.